		11	9 Defent and			PTO/SB/21 (09-04) e through 07/31/2008, OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE	
Under the Paperwork Reduction Act of 19	35, no person	as are required to respond to a Application Number	collection of	niomation	uniess	it displays a valid OMB control number.	
TDANIE ST			10/088	10/088,250			
TRANSMITTAL		Filing Date	Decem	December 23, 2002			
FORM		First Named Inventor	David	David M. FINK, et al			
j		Art Unit	1626	1626			
(to be used for all correspondence after initial filing)		Examiner Name	Golam	Golam M. SHAMEEM			
Total Number of Pages in This Submission	18	Attorney Docket Numbe	r USHM	USHMR2023 US PCT			
ENCLOSURES (Check all that apply)							
Fee Transmittal Form		Drawing(s)			After	Allowance Communication to TC	
Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply					Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final L. P		Petition to Convert to a Provisional Application		Propi	ietary Information		
Affidavits/declaration(s)	Affidavits/declaration(s) Powe Chan				_	s Leiter	
		Change of Correspondence	eminal Disclaimer		Other	Enclosure(s) (please Identify	
					below	<u>'):</u>	
Express Abandonment Request	in	Request for Refund		-			
Information Disclosure Statement	ᅵᅛᆞ	CD, Number of CD(s)					
<b></b>	<u></u> _	Landscape Table on (	CD	ļ.			
Certified Copy of Priority Document(s)  Remark		<del></del>					
Reply to Missing Parts/ Incomplete Application Incomplete Incomp							
Incomplete Application Reply to Missing Parts							
under 37 CFR 1.52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name  AVENTIS PHARMACEUTICALS INC.							
Signature 20							
Printed name Barbara E. KURYS							
Date Rea No. 1							
May 20, 2005			1.09.110.	34650			
CERTIFICATE OF TRANSMISSION/MAILING							
hereby certify that this correspondence is being facelinite to promitted to the USCOTO							
sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO, 571-273-0706 ; Total No, of Pages Transmitted: 18							
Signature Quantic Steen							
Typed or printed name Bonnie Stein		The state of the s	<del></del> _		Date	May 20, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the including comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

SHAMEEM, Golam M.

David M. FINK, et al.

Art Unit:

1626

Application No.:

10/088,250

Filed:

December 23, 2002

TELEFAX CERTIFICATE

Title:

THIENOSOXAZOLYL-AND

THIENYLPYRRAZOLYL PHENOXY

SUBSTITUTED PROPYL

DERIVATIVES USEFULE AS D4

ANTAGONISTS

I hereby certify that this correspondence is being transmitted via factsimile to the Commissioner for Patents, Alexandria, VA 22313, on

May 20, 2005

Bornie Strin Goance Signature

## AMENDMENT AND REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is responsive to the telephone call received from the Examiner on May 19, 2005, concerning a revised restriction requirement in relation to the captioned patent application.